Randomized Trial of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF-Mutant Metastatic Colorectal Cancer (SWOG S1406)

Kopetz, Scott; A. Guthrie, Katherine; K. Morris, Van; Lenz, Heinz‐Josef; M. Magliocco, Anthony; M. Maru, Dipen; Yan, Yibing; B. Lanman, Richard; C. Manyam, Ganiraju; S. Hong, David; V. Sorokin, Alexey; E. Atreya, Chloé; A. Díaz, Luis; J. Allegra, Carmen; Raghav, Kanwal; E Wang, Stephen; H. Lieu, Christopher; McDonough, Shannon; A. Philip, Philip; S. Höchster, Howard

doi:10.1200/jco.20.01994

Public

Randomized Trial of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF-Mutant Metastatic Colorectal Cancer (SWOG S1406)

Published in Journal of Clinical Oncology • Dec 23, 2020

Authors:

Scott Kopetz

Katherine A. Guthrie

Van K. Morris

Abstract

PURPOSE BRAF V600E mutations are rarely associated with objective responses to the BRAF inhibitor vemurafenib in patients with metastatic colorectal cancer (CRC). Blockade of BRAF V600E by vemurafenib causes feedback upregulation of EGFR, whose signaling activities can be impeded by cetuximab. METHO...

Subject

Vemurafenib

Cetuximab

Medicine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!